1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed) is sponsored by NIH Gabriella Miller Kids First Pediatric Research Program. This grant supports research focused on the secondary analysis and integration of existing data to understand cancer risk and related outcomes, particularly relevant for pediatric cancer research.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - Discovery of the Genetic Basis of Childhood Cancers and of Congenital Anomalies: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed) Discovery of the Genetic Basis of Childhood Cancers and of Congenital Anomalies: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed) Agency: National Institutes of Health Assistance Listings: 93.
310 -- Trans-NIH Research Support Last Updated: June 18, 2026 View version history on Grants. gov As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First Program), the NIH invites applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First Program supported genomic data generating centers.
Applicants are encouraged to propose sequencing of existing pediatric cancer or congenital anomaly cohorts to elucidate the genetic contribution (somatic and/or germline) to childhood cancers, to investigate the genetic etiology of congenital anomalies, to study the molecular basis of the associations between congenital anomalies and increased...
cancer risk, or to expand the range of pediatric disorders included within the Kids First Data Resource. The program will accept applications that propose whole genome, exome, and transcriptome sequencing, as well as clinical-grade sequencing, long-read sequencing, proteomics, and epigenomic assays of tumor or affected tissue, when justified.
Applicants are encouraged to propose cohorts to increase representation of existing Kids First Program projects. These data, and associated clinical and phenotypic data, will become part of the Kids First Data Resource Center for sharing with the research community.
Special district governments Public and Indian housing authorities Federally recognized Native American tribal governments City or township governments Nonprofits non-higher education with 501(c)(3) Nonprofits non-higher education without 501(c)(3) Other Native American tribal organizations For-profit organizations other than small businesses Public and state institutions of higher education Independent school districts Private institutions of higher education Refer to Section III.
Eligibility Information in the NOFO for additional information on eligibility. Foreign Organizations/Foreign CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. Grantor contact information Gabriella Miller Kids First Program File name Description Last updated PAR-27-071-Full-Announcement. html PAR-27-071-Full-Announcement.
html Jun 18, 2026 06:23 PM UTC Link to additional information Closing: January 11, 2027 Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Your account requires additional identity verification.
According to the current listing, eligibility includes: Investigators at academic, medical, or research institutions. Confirm the full requirements in the official notice before applying.
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed) is funded by NIH Gabriella Miller Kids First Pediatric Research Program. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Investigator Initiated Innovation in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed) is sponsored by NIH Gabriella Miller Kids First Pediatric Research Program. This opportunity supports innovative computational genomics and data science research initiated by investigators, which can be highly relevant for analyzing large datasets in pediatric cancer and rare diseases.
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed) is sponsored by NIH Gabriella Miller Kids First Pediatric Research Program. This grant supports exploratory and developmental research projects that involve secondary analysis and integration of existing data to elucidate cancer risk and related outcomes, with a focus on pediatric populations.
Screening and Functional Validation of Genomic Variants Associated with Human Congenital Anomalies (R01 Clinical Trial Not Allowed) is sponsored by NIH Gabriella Miller Kids First Pediatric Research Program. This grant focuses on screening and functional validation of genomic variants linked to human congenital anomalies. Given the shared genetic pathways between childhood cancer and birth defects, this can be relevant to St.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article